Cargando…
A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor
Background: Simmitecan is a potent inhibitor of topoisomerase I with anti-tumor activity. This phase Ib trial was conducted to investigate the safety and anti-tumor effect of simmitecan alone or in combination with other drugs. Methods: Eligible patients with advanced solid tumor had no further stan...
Autores principales: | Zhang, Qi, Deng, Ting, Yang, Fen, Guo, Weijian, Liu, Dan, Yuan, Jiajia, Qi, Changsong, Cao, Yanshuo, Yu, Qiuqiong, Cai, Huiming, Peng, Zhi, Wang, Xicheng, Zhou, Jun, Lu, Ming, Gong, Jifang, Li, Jian, Ba, Yi, Shen, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355729/ https://www.ncbi.nlm.nih.gov/pubmed/35935841 http://dx.doi.org/10.3389/fphar.2022.833583 |
Ejemplares similares
-
Survival benefit of preoperative hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin followed by hepatectomy for hepatocellular carcinoma
por: Hu, Zili, et al.
Publicado: (2023) -
Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma
por: Zhang, Haixia, et al.
Publicado: (2022) -
The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients.
por: DeLap, R. J.
Publicado: (1988) -
Evaluation of Antiemetic Therapy for Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin
por: Zhao, Yang, et al.
Publicado: (2021) -
Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs
por: OCHIAI, TAKUMI, et al.
Publicado: (2013)